TFCP2, transcription factor CP2, 7024

N. diseases: 46; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0220630
Disease: Adult Liver Carcinoma
Adult Liver Carcinoma
0.010 Biomarker disease BEFREE Recently, we reported that the protumourigenic roles of YAP in liver cancer are indispensable for transcription factor CP2 (TFCP2) in a Hippo-independent manner; however, proteins that act upstream to simultaneously control YAP and TFCP2 remain unclear. 31501420 2019
CUI: C0240602
Disease: opioid use
opioid use
0.010 Biomarker disease BEFREE Patients with degenerative hip and lumbar spine pathology that undergo THA prior to LSF have a significantly increased risk of postoperative dislocation, infection, revision surgery, and prolonged opioid use compared to THA after LSF. 31809465 2019
Liver and Intrahepatic Biliary Tract Carcinoma
0.010 Biomarker disease BEFREE Recently, we reported that the protumourigenic roles of YAP in liver cancer are indispensable for transcription factor CP2 (TFCP2) in a Hippo-independent manner; however, proteins that act upstream to simultaneously control YAP and TFCP2 remain unclear. 31501420 2019
Squamous cell carcinoma of esophagus
0.010 AlteredExpression disease BEFREE High expression of MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) in ESCC tissues suggests promoting ESCC progression and poor prognosis, co-expression of MAGE-A11 and transcription factors even worse. 31126819 2019
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver
0.010 Biomarker disease BEFREE Recently, we reported that the protumourigenic roles of YAP in liver cancer are indispensable for transcription factor CP2 (TFCP2) in a Hippo-independent manner; however, proteins that act upstream to simultaneously control YAP and TFCP2 remain unclear. 31501420 2019
Secondary malignant neoplasm of liver
0.010 Biomarker disease BEFREE To evaluate the feasibility of a same-day yttrium-90 (<sup>90</sup>Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases. 30819470 2019
CUI: C1266134
Disease: Spindle cell rhabdomyosarcoma
Spindle cell rhabdomyosarcoma
0.010 GeneticVariation disease BEFREE The final diagnosis was spindle cell rhabdomyosarcoma of a lumbar vertebra with a FUS-TFCP2 fusion. 30948206 2019
CUI: C1384494
Disease: Metastatic Carcinoma
Metastatic Carcinoma
0.010 Biomarker group BEFREE A spindle cell rhabdomyosarcoma with a FUS-TFCP2 fusion in a vertebral bone is rare and should be differentiated from metastatic carcinoma, particularly in the elderly. 30948206 2019
CUI: C4722419
Disease: Extrapulmonary Small Cell Carcinoma
Extrapulmonary Small Cell Carcinoma
0.010 AlteredExpression disease BEFREE Expression and prognostic significance of MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) in ESCC tissues. 31126819 2019
CUI: C0220611
Disease: Childhood Rhabdomyosarcoma
Childhood Rhabdomyosarcoma
0.010 GeneticVariation disease BEFREE Spindle cell rhabdomyosarcomas carrying the FUS-TFCP2 fusion are very rare rhabdomyosarcoma variants with osseous predilection. 29758589 2018
CUI: C0279550
Disease: Adult Rhabdomyosarcoma
Adult Rhabdomyosarcoma
0.010 GeneticVariation disease BEFREE Spindle cell rhabdomyosarcomas carrying the FUS-TFCP2 fusion are very rare rhabdomyosarcoma variants with osseous predilection. 29758589 2018
CUI: C0014544
Disease: Epilepsy
Epilepsy
0.010 AlteredExpression disease BEFREE We report that suppressed TFCP2 expression and elevated ASIC2a expression were associated with glucose hypometabolism in the hippocampi of humans with epilepsy and of rat epilepsy model brains. 28725010 2017
CUI: C0030193
Disease: Pain
Pain
0.010 AlteredExpression phenotype BEFREE Despite the subjective pain sensation being unaltered, the two anodal (real) interventions significantly decreased OP activity associated with pain-SEFs. 28719422 2017
CUI: C0036572
Disease: Seizures
Seizures
0.010 AlteredExpression phenotype BEFREE Our findings suggest that hippocampal glucose hypometabolism elevates ASIC2a expression by suppressing TFCP2 expression, which further enhances the intrinsic excitability of CA1 pyramidal neurons and increases seizure susceptibility in patients with temporal lobe epilepsy. 28725010 2017
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.010 AlteredExpression disease BEFREE We have shown that the transcription factor TFCP2 was up-regulated in the pancreatic cancer. 29050300 2017
CUI: C0239589
Disease: Pain in finger
Pain in finger
0.010 Biomarker phenotype BEFREE Somatosensory-evoked magnetic fields following noxious intraepidermal electrical stimulation to the left index finger (pain-SEFs) were recorded before and after tDCS with a single-blind, sham-controlled, cross-over trial design. 28719422 2017
CUI: C0341439
Disease: Chronic liver disease
Chronic liver disease
0.010 Biomarker group BEFREE Here, we genotyped 7 SNPs of TFCP2 in a case-control study of 119 patients with HCC and 200 patients with chronic liver disease. 28348581 2017
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas
0.010 AlteredExpression disease BEFREE We have shown that the transcription factor TFCP2 was up-regulated in the pancreatic cancer. 29050300 2017
CUI: C0025202
Disease: melanoma
melanoma
0.010 Biomarker disease BEFREE Transcription factor LSF (TFCP2) inhibits melanoma growth. 26506241 2016
CUI: C1512409
Disease: Hepatocarcinogenesis
Hepatocarcinogenesis
0.010 Biomarker disease BEFREE The identification of global targets, molecular pathways and networks associated with TFCP2, together with the discovery of the effect of TFCP2 on FN1 and TJP1 that are involved in metastasis, adds to our understanding of the mechanisms that determine a highly aggressive and metastatic phenotype in hepatocarcinogenesis. 25609232 2015
CUI: C1519670
Disease: Tumor Angiogenesis
Tumor Angiogenesis
0.010 AlteredExpression phenotype BEFREE LSF is a transcription factor regulating gene expression of angiogenesis, tumor invasion and proliferation, and is identified as a chemoresistant gene. 25337247 2014
CUI: C0013080
Disease: Down Syndrome
Down Syndrome
0.010 AlteredExpression disease BEFREE Potential interaction between the GARS-AIRS-GART Gene and CP2/LBP-1c/LSF transcription factor in Down syndrome-related Alzheimer disease. 17902044 2007
CUI: C4521042
Disease: Complete Trisomy 21 Syndrome
Complete Trisomy 21 Syndrome
0.010 AlteredExpression disease BEFREE Potential interaction between the GARS-AIRS-GART Gene and CP2/LBP-1c/LSF transcription factor in Down syndrome-related Alzheimer disease. 17902044 2007
CUI: C0524851
Disease: Neurodegenerative Disorders
Neurodegenerative Disorders
0.010 AlteredExpression group BEFREE In young PSP patients, the H1B risk could be localized to a 22 kb regulatory region in intron 0 (P<0.001) and could be fully explained by one SNP, htSNP167, creating a LBP-1c/LSF/CP2 site, shown to regulate the expression of genes in other neurodegenerative disorders. 16195395 2005
CUI: C0023440
Disease: Acute Erythroblastic Leukemia
Acute Erythroblastic Leukemia
0.010 AlteredExpression disease BEFREE We now report the biochemical purification of SSP from K562 cell nuclear extract and demonstrate that the ubiquitously expressed transcription factor CP2 is pivotal to, but not sufficient for, SSP binding activity. 7828600 1995